Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Kalvista Pharmaceuticals Inc (KALV)

Kalvista Pharmaceuticals Inc (KALV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 596,033
  • Shares Outstanding, K 17,942
  • Annual Sales, $ 12,690 K
  • Annual Income, $ -29,120 K
  • 60-Month Beta 2.04
  • Price/Sales 48.99
  • Price/Cash Flow N/A
  • Price/Book 9.37
Trade KALV with:

Options Overview

Details
  • Implied Volatility 109.32%
  • Historical Volatility 273.73%
  • IV Percentile 20%
  • IV Rank 9.85%
  • IV High 392.70% on 11/10/20
  • IV Low 78.37% on 11/27/20
  • Put/Call Vol Ratio 2.57
  • Today's Volume 182
  • Volume Avg (30-Day) 3,485
  • Put/Call OI Ratio 2.29
  • Today's Open Interest 3,047
  • Open Int (30-Day) 21,951

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 01/31/21
See More
  • Average Estimate -0.60
  • Number of Estimates 5
  • High Estimate -0.57
  • Low Estimate -0.64
  • Prior Year -0.52
  • Growth Rate Est. (year over year) -15.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.33 +129.38%
on 02/04/21
45.00 -26.96%
on 02/09/21
+16.52 (+101.04%)
since 01/26/21
3-Month
14.33 +129.38%
on 02/04/21
45.00 -26.96%
on 02/09/21
+14.26 (+76.63%)
since 11/25/20
52-Week
5.61 +486.44%
on 03/18/20
45.00 -26.96%
on 02/09/21
+19.11 (+138.88%)
since 02/26/20

Most Recent Stories

More News
KalVista Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced...

KALV : 32.87 (-1.05%)
KalVista Pharmaceuticals Announces the Closing of its Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the closing of its previously announced upsized public offering of 6,181,250 shares of its common stock at a price to the public of $36.00...

KALV : 32.87 (-1.05%)
KalVista Pharmaceuticals Announces Pricing of an Upsized $193.5 Million Public Offering of Common Stock

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the pricing of its upsized underwritten public offering of 5,375,000 shares of its common stock at a price to the public of $36.00 per share....

KALV : 32.87 (-1.05%)
Global Human Papillomavirus (HPV) Vaccine Market Could Exceed $12 Billion By 2027

, /PRNewswire/ -- The incidence of cancer is increasing every year and it has been the major factor for the growth of the cancer vaccines market. Healthcare physicians are looking for alternate therapies,...

BIOV.CN : 0.560 (+9.80%)
LMNGF : 0.4473 (+10.15%)
KALV : 32.87 (-1.05%)
HTBX : 7.98 (+0.88%)
BMS : 57.25 (-1.43%)
TYME : 2.00 (-4.76%)
ONTX : 1.2500 (-8.09%)
KalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) announced today that it intends to offer and sell 4,500,000 shares of its common stock in an underwritten public offering. In addition, KalVista intends to...

KALV : 32.87 (-1.05%)
KalVista Pharmaceuticals Reports Positive Results for KVD900 Phase 2 Demonstrating Statistically and Clinically Significant Responses Across All Endpoints as an Oral On-Demand Treatment for HAE Attacks

--- KVD900 Generally Safe and Well-Tolerated -

KALV : 32.87 (-1.05%)
Frazier Healthcare Partners Adds Highly Experienced Investor to Life Sciences Team

Frazier Healthcare Partners announced the planned addition of Albert Cha, M.D., Ph.D. as Managing Partner on the Life Sciences team. He has over 20 years of experience investing in public and private biopharmaceutical...

AGN : 193.02 (+0.02%)
ASND : 154.97 (-2.33%)
KALV : 32.87 (-1.05%)
ACRS : 22.28 (+5.00%)
BHVN : 84.98 (+2.20%)
MNLO : 1.3500 (-2.17%)
SRRA : 14.74 (+1.83%)
BIOD : 0.65 (+6.56%)
Notable Thursday Option Activity: KALV, MAC, ETSY

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in KalVista Pharmaceuticals Inc , where a total of 2,647 contracts have traded so far, representing...

KALV : 32.87 (-1.05%)
Are Options Traders Betting on a Big Move in KalVista Pharmaceuticals (KALV) Stock?

Investors need to pay close attention to KalVista Pharmaceuticals (KALV) stock based on the movements in the options market lately.

KALV : 32.87 (-1.05%)
Global Diabetic Retinopathy Market Report 2020: Insights, Epidemiology, and Market Report 2017-2030 Featuring 11 Emerging Therapies

, /PRNewswire/ -- The drug pipelines has been added to offering.

ADVM : 12.83 (+2.48%)
KALV : 32.87 (-1.05%)
NVS : 85.91 (-0.92%)
REGN : 450.57 (-0.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

KalVista Pharmaceuticals, Inc. is a pharmaceuticals company. It engages in discovery, development and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product portfolio consist hereditary angioedema and diabetic macular edema, KVD818 and KVD001, which...

See More

Key Turning Points

3rd Resistance Point 36.12
2nd Resistance Point 35.22
1st Resistance Point 34.04
Last Price 32.87
1st Support Level 31.96
2nd Support Level 31.06
3rd Support Level 29.88

See More

52-Week High 45.00
Last Price 32.87
Fibonacci 61.8% 29.95
Fibonacci 50% 25.30
Fibonacci 38.2% 20.65
52-Week Low 5.61

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar